151 related articles for article (PubMed ID: 7658750)
41. Inhibition of protein kinase C by semisynthetic phospholipid plasmanyl-(N-acyl)-ethanolamine, a nontoxic antitumor preparation.
Mikhaevich IS; Gerasimova GK; Kára J
Biochem Int; 1991 Jan; 23(2):215-20. PubMed ID: 1859429
[TBL] [Abstract][Full Text] [Related]
42. Searching for the role of membrane sphingolipids in selectivity of antitumor ether lipid-edelfosine.
Hac-Wydro K; Dynarowicz-Łatka P
Colloids Surf B Biointerfaces; 2010 Dec; 81(2):492-7. PubMed ID: 20719476
[TBL] [Abstract][Full Text] [Related]
43. Fas/CD95 death receptor and lipid rafts: new targets for apoptosis-directed cancer therapy.
Mollinedo F; Gajate C
Drug Resist Updat; 2006; 9(1-2):51-73. PubMed ID: 16687251
[TBL] [Abstract][Full Text] [Related]
44. Antitumor activity of SRI 62-834, a cyclic ether analog of ET-18-OCH3.
Houlihan WJ; Lee ML; Munder PG; Nemecek GM; Handley DA; Winslow CM; Happy J; Jaeggi C
Lipids; 1987 Nov; 22(11):884-90. PubMed ID: 2832680
[TBL] [Abstract][Full Text] [Related]
45. Biological effects of alkylglycerols.
Weber N
Prog Biochem Pharmacol; 1988; 22():48-57. PubMed ID: 3043435
[No Abstract] [Full Text] [Related]
46. Ether lipids and analogs in experimental cancer therapy. A brief review of the Munich experience.
Berdel WE
Lipids; 1987 Nov; 22(11):970-3. PubMed ID: 3328030
[TBL] [Abstract][Full Text] [Related]
47. In vivo antitumor activity of ilmofosine.
Herrmann DB; Pahlke W; Opitz HG; Bicker U
Cancer Treat Rev; 1990 Sep; 17(2-3):247-52. PubMed ID: 2272040
[TBL] [Abstract][Full Text] [Related]
48. Anticancer Agent Edelfosine Exhibits a High Affinity for Cholesterol and Disorganizes Liquid-Ordered Membrane Structures.
Ausili A; Martínez-Valera P; Torrecillas A; Gómez-Murcia V; de Godos AM; Corbalán-García S; Teruel JA; Gómez Fernández JC
Langmuir; 2018 Jul; 34(28):8333-8346. PubMed ID: 29924618
[TBL] [Abstract][Full Text] [Related]
49. Effects of the anti-neoplastic agent ET-18-OCH3 and some analogs on the biophysical properties of model membranes.
Torrecillas A; Aroca-Aguilar JD; Aranda FJ; Gajate C; Mollinedo F; Corbalán-García S; de Godos A; Gómez-Fernández JC
Int J Pharm; 2006 Aug; 318(1-2):28-40. PubMed ID: 16624506
[TBL] [Abstract][Full Text] [Related]
50. Antitumoral alkylphospholipids alter cell lipid metabolism.
Marco C; Ríos-Marco P; Jiménez-López JM; Segovia JL; Carrasco MP
Anticancer Agents Med Chem; 2014 May; 14(4):545-58. PubMed ID: 24628237
[TBL] [Abstract][Full Text] [Related]
51. Molecular dynamics of antitumor ether-linked phospholipids in model membranes: a spin-label study.
Lai CS; Joseph J; Shih CC
Biochem Biophys Res Commun; 1989 May; 160(3):1189-95. PubMed ID: 2543392
[TBL] [Abstract][Full Text] [Related]
52. The alkyl-lysophospholipid, ET-18-OCH3 synergistically enhances the Merocyanine 540-mediated photoinactivation of leukemia cells: implications for the extracorporeal purging of autologous hematopoietic stem cells.
Yamazaki T; Sieber F
Bone Marrow Transplant; 1997 Jan; 19(2):113-9. PubMed ID: 9116607
[TBL] [Abstract][Full Text] [Related]
53. Ether lipids in cancer chemotherapy.
Berdel WE; Okamoto S
Keio J Med; 1990 Jun; 39(2):75-8. PubMed ID: 2214502
[TBL] [Abstract][Full Text] [Related]
54. Cyclic oxygen analogues of alkyl-lysophospholipids. Synthesis and neoplastic cell growth inhibitory properties.
Houlihan WJ; Lee ML; Munder PG; Winslow CM; Cheon SH; D'Aries FJ; DeLillo AK; Jaeggi CS; Mason RB; Parrino VA
J Lipid Mediat; 1990; 2(5):295-307. PubMed ID: 2133273
[TBL] [Abstract][Full Text] [Related]
55. New cytostatics with experimentally different toxic profiles.
Berger MR; Muschiol C; Schmähl D; Eibl HJ
Cancer Treat Rev; 1987 Dec; 14(3-4):307-17. PubMed ID: 3440252
[No Abstract] [Full Text] [Related]
56. Fluorescent phenylpolyene analogues of the ether phospholipid edelfosine for the selective labeling of cancer cells.
Quesada E; Delgado J; Gajate C; Mollinedo F; Acuña AU; Amat-Guerri F
J Med Chem; 2004 Oct; 47(22):5333-5. PubMed ID: 15481970
[TBL] [Abstract][Full Text] [Related]
57. Surface-active properties of the antitumour ether lipid 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine (edelfosine).
Busto JV; Sot J; Goñi FM; Mollinedo F; Alonso A
Biochim Biophys Acta; 2007 Jul; 1768(7):1855-60. PubMed ID: 17543274
[TBL] [Abstract][Full Text] [Related]
58. Antileishmanial activity of the ether phospholipid ilmofosine.
Croft SL; Neal RA; Thornton EA; Herrmann DB
Trans R Soc Trop Med Hyg; 1993; 87(2):217-9. PubMed ID: 8337733
[TBL] [Abstract][Full Text] [Related]
59. Cytotoxic activity of the thioether phospholipid analogue BM 41.440 in primary human tumor cultures.
Herrmann DB; Neumann HA
Lipids; 1987 Nov; 22(11):955-7. PubMed ID: 3444392
[TBL] [Abstract][Full Text] [Related]
60. Transferrin-conjugated polymeric nanomedicine to enhance the anticancer efficacy of edelfosine in acute myeloid leukemia.
Sun Y; Sun ZL
Biomed Pharmacother; 2016 Oct; 83():51-57. PubMed ID: 27470549
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
